Stocks of testosterone replacement therapy Testogel in pumps and sachets have been increased in Australia to meet patient need.
Besins Healthcare, manufacturer of Testogel (1% transdermal testosterone gel) has confirmed full availability of pump and sachet formulations. This alert has been issued in response to the supply-shortage notification issued by the TGA for the following:
- Reandron 1000 testosterone undecanoate 1000mg in 4ml oily solution for injection vial (supply shortage from October 1 to December 31, 2018).
- Primoteston Depot testosterone enantate 250mg/1ml injection syringe (supply shortage from August 27, 2018 to March 31, 2019).
Besins estimates that up to 20,000 Australian patients may be affected by shortages of Reandron and Primoteston.
“We want to assure clinicians concerned by supply shortages of injectable testosterone products that Testogel is unaffected by these shortages,” Besins Healthcare Managing Director Geoff Blundell said.
“We are pleased to confirm that wholesalers have access to ample stock of both the Testogel pump and sachet formulations to meet increased need during this period.
“We are working hard to ensure that doctors have access to therapeutic options for continuation of therapy for their patients with clinically significant testosterone deficiency.”
Therapeutic Goods Administration. Medicine Shortages Information Initiative, available at https://apps.tga.gov.au/Prod/msi/Search/ (search for testosterone).